Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

BACKGROUND: Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Groves, M D, Puduvalli, V K, Gilbert, M R, Levin, V A, Conrad, C A, Liu, V H, Hunter, K, Meyers, C, Hess, K R, Alfred Yung, W K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736828/
https://www.ncbi.nlm.nih.gov/pubmed/19672263
http://dx.doi.org/10.1038/sj.bjc.6605189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736828/
https://www.ncbi.nlm.nih.gov/pubmed/19672263
http://dx.doi.org/10.1038/sj.bjc.6605189

Ejemplares similares